Oppenheimer Upgrades Ventyx Biosciences to Outperform, Announces $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has upgraded Ventyx Biosciences (VTYX) from Perform to Outperform, setting a price target of $12.
March 12, 2024 | 8:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ventyx Biosciences was upgraded by Oppenheimer from Perform to Outperform with a new price target of $12.
Upgrades by reputable analysts like Oppenheimer often lead to positive short-term price movements. The upgrade from Perform to Outperform, coupled with a specific price target of $12, suggests a strong bullish outlook for VTYX. This can increase investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100